A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
This is a multicenter, open label, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.
Solid Tumor, Adult
DRUG: CS3006
Number of participants with adverse events, From the day of first dose to 30 days after last dose of CS3006
This is a multicenter, open label, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.